Literature DB >> 28581473

Minimal residual disease assessment by next-generation sequencing. Better tools to gaze into the crystal ball?

A Balduzzi1.   

Abstract

Mesh：

Year:  2017        PMID： 28581473     DOI： 10.1038/bmt.2017.104

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  16 in total

1.  Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation.

Authors:  A C Lankester; M B Bierings; E R van Wering; A J M Wijkhuijs; R A de Weger; J T Wijnen; J M Vossen; B Versluys; R M Egeler; M J D van Tol; H Putter; T Révész; J J M van Dongen; V H J van der Velden; M W Schilham
Journal:  Leukemia       Date:  2010-06-10       Impact factor: 11.528

2.  Non-specific amplification of patient-specific Ig/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring.

Authors:  V H J van der Velden; J M Wijkhuijs; J J M van Dongen
Journal:  Leukemia       Date:  2007-09-13       Impact factor: 11.528

3.  The Value of Minimal Residual Disease (and Diamonds).

Authors:  Adriana Balduzzi
Journal:  Biol Blood Marrow Transplant       Date:  2016-11-16       Impact factor: 5.742

4.  Chimerism versus minimal residual disease monitoring after allogeneic transplantation--when do we act and will intervention improve outcomes?

Authors:  Michael A Pulsipher
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-29       Impact factor: 5.742

5.  Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.

Authors:  Rosemary Sutton; Peter J Shaw; Nicola C Venn; Tamara Law; Anuruddhika Dissanayake; Tatjana Kilo; Michelle Haber; Murray D Norris; Chris Fraser; Frank Alvaro; Tamas Revesz; Toby N Trahair; Luciano Dalla-Pozza; Glenn M Marshall; Tracey A O'Brien
Journal:  Br J Haematol       Date:  2014-10-14       Impact factor: 6.998

6.  Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation.

Authors:  Eva Rettinger; Michael Merker; Emilia Salzmann-Manrique; Hermann Kreyenberg; Thomas Krenn; Matthias Dürken; Jörg Faber; Sabine Huenecke; Claudia Cappel; Melanie Bremm; Andre Willasch; Shahrzad Bakhtiar; Andrea Jarisch; Jan Soerensen; Thomas Klingebiel; Peter Bader
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-11       Impact factor: 5.742

7.  Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?

Authors:  M A Pulsipher; B Langholz; D A Wall; K R Schultz; N Bunin; W Carroll; E Raetz; S Gardner; R K Goyal; J Gastier-Foster; M Borowitz; D Teachey; S A Grupp
Journal:  Bone Marrow Transplant       Date:  2015-05-11       Impact factor: 5.483

8.  NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.

Authors:  Jeffrey S Miller; Edus H Warren; Marcel R M van den Brink; Jerome Ritz; Warren D Shlomchik; William J Murphy; A John Barrett; Hans Jochem Kolb; Sergio Giralt; Michael R Bishop; Bruce R Blazar; J H Frederik Falkenburg
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-10       Impact factor: 5.742

9.  Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

Authors:  V H J van der Velden; G Cazzaniga; A Schrauder; J Hancock; P Bader; E R Panzer-Grumayer; T Flohr; R Sutton; H Cave; H O Madsen; J M Cayuela; J Trka; C Eckert; L Foroni; U Zur Stadt; K Beldjord; T Raff; C E van der Schoot; J J M van Dongen
Journal:  Leukemia       Date:  2007-02-08       Impact factor: 11.528

10.  B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL.

Authors:  E Fronkova; K Muzikova; E Mejstrikova; M Kovac; R Formankova; P Sedlacek; O Hrusak; J Stary; J Trka
Journal:  Bone Marrow Transplant       Date:  2008-05-19       Impact factor: 5.483
View more
  1 in total

Review 1.  [Clinical application of minimal residual disease detection in childhood acute leukemia].

Authors:  Yan-Qin Cheng; Xiao-Wen Zhai
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2018-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.